These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 35820038)

  • 1. Barriers to healthcare workers reporting adverse events following immunization in Zhejiang province, China.
    Lv H; Pan X; Wang Y; Liang H; Yu H
    Hum Vaccin Immunother; 2022 Nov; 18(5):2083865. PubMed ID: 35820038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Barriers to healthcare workers reporting adverse events following immunization in four regions of Ghana.
    Gidudu JF; Shaum A; Dodoo A; Bosomprah S; Bonsu G; Amponsa-Achiano K; Darko DM; Sabblah G; Opare J; Nyaku M; Owusu-Boakye B; Oduro A; Aborigo R; Conklin L; Welaga P; Ampadu HH
    Vaccine; 2020 Jan; 38(5):1009-1014. PubMed ID: 31787409
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of adverse events following immunization in Zhejiang, China, 2019: a retrospective cross-sectional study based on the passive surveillance system.
    Pan X; Lv H; Chen F; Wang Y; Liang H; Shen L; Chen Y; Hu Y
    Hum Vaccin Immunother; 2021 Oct; 17(10):3823-3830. PubMed ID: 34170800
    [No Abstract]   [Full Text] [Related]  

  • 4. Surveillance for adverse events following immunization from 2008 to 2011 in Zhejiang Province, China.
    Hu Y; Li Q; Lin L; Chen E; Chen Y; Qi X
    Clin Vaccine Immunol; 2013 Feb; 20(2):211-7. PubMed ID: 23239804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of 'SAEFVIC', A Pharmacovigilance Surveillance Scheme for the Spontaneous Reporting of Adverse Events Following Immunisation in Victoria, Australia.
    Clothier HJ; Crawford NW; Russell M; Kelly H; Buttery JP
    Drug Saf; 2017 Jun; 40(6):483-495. PubMed ID: 28342074
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Surveillance of adverse events following immunization of 13-valent pneumococcal conjugate vaccine among infants, in Zhejiang province, China.
    Hu Y; Pan X; Chen F; Wang Y; Liang H; Shen L; Chen Y; Lv H
    Hum Vaccin Immunother; 2022 Dec; 18(1):2035141. PubMed ID: 35240930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Understanding reporting practices and perceptions of barriers in adverse events following immunisation surveillance: A cross-sectional survey of paediatricians in Kerala, India.
    Thomas RA; Rajan Joseph M; Castilloux AM; Moride Y
    Vaccine; 2021 Jul; 39(33):4678-4684. PubMed ID: 34238607
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of the surveillance system for adverse events following immunisation in the Gaza Strip: a cross-sectional study.
    Awad JA; Dhair MI; Ghuneim NI; Abu Ali K; Al-Yaqoubi YS; Abu Rabee' M; Sarsour A
    Lancet; 2021 Jul; 398 Suppl 1():S27. PubMed ID: 34227959
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimising reporting of adverse events following immunisation by healthcare workers in Ghana: A qualitative study in four regions.
    Aborigo RA; Welaga P; Oduro A; Shaum A; Opare J; Dodoo A; Ampadu H; Gidudu JF
    PLoS One; 2022; 17(12):e0277197. PubMed ID: 36538549
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and feasibility of SMS m-Health for the detection of adverse events following immunisation (AEFIs) in resource-limited setting-The Zimbabwe stimulated telephone assisted rapid safety surveillance (Zm-STARSS) randomised control trial.
    Nyambayo PPM; Gold MS; Mehta UC; Clarke S; Manyevere R; Chirinda L; Zifamba EN; Nyamandi T
    Vaccine; 2023 Oct; 41(45):6700-6709. PubMed ID: 37805357
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of death cases in Shenyang City, China, for immunization adverse event surveillance, 2009-2021.
    Gao D; Dong G; Zhu L; Jia N; Sun B
    Hum Vaccin Immunother; 2023 Aug; 19(2):2263225. PubMed ID: 37782096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Surveillance on the adverse events following immunization with the pentavalent vaccine in Zhejiang, China.
    Pan X; Lv H; Liang H; Wang Y; Shen L; Chen F; Chen Y; Hu Y
    Hum Vaccin Immunother; 2022 Dec; 18(1):2021711. PubMed ID: 35108152
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Awareness and utilization of reporting pathways for adverse events following immunization: online survey among pediatricians in Russia and Germany.
    Muehlhans S; von Kleist M; Gretchukha T; Terhardt M; Fegeler U; Maurer W; Namazova-Baranova L; Gaedicke G; Baranov A; Rath B
    Paediatr Drugs; 2014 Aug; 16(4):321-30. PubMed ID: 24849291
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Post-licensure safety monitoring of quadrivalent human papillomavirus vaccine using the national adverse event following immunization surveillance system from Zhejiang province, 2018-2020.
    Hu Y; Pan X; Shen L; Chen F; Wang Y; Liang H; Chen Y; Lv H
    Hum Vaccin Immunother; 2021 Dec; 17(12):5447-5453. PubMed ID: 34613883
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A survey of knowledge and reporting practices of primary healthcare workers on adverse experiences following immunisation in alimosho local government area, Lagos.
    Ogunyemi RA; Odusanya OO
    Niger Postgrad Med J; 2016; 23(2):79-85. PubMed ID: 27424618
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A scoping review of active, participant-centred, digital adverse events following immunization (AEFI) surveillance: A Canadian immunization research network study.
    Psihogios A; Brianne Bota A; Mithani SS; Greyson D; Zhu DT; Fung SG; Wilson SE; Fell DB; Top KA; Bettinger JA; Wilson K
    Vaccine; 2022 Jul; 40(31):4065-4080. PubMed ID: 35680501
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of a new global indicator for vaccine safety surveillance and trends in adverse events following immunization reporting 2000-2015.
    Lei J; Balakrishnan MR; Gidudu JF; Zuber PLF
    Vaccine; 2018 Mar; 36(12):1577-1582. PubMed ID: 29454518
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Understanding and experience of adverse event following immunization (AEFI) and its consequences among healthcare providers in Kebbi State, Nigeria: a qualitative study.
    Omoleke SA; Getachew B; Isyaku A; Aliyu AB; Mustapha AM; Dansanda SM; Kanmodi KK; Abubakar H; Lawal ZI; Kangiwa HA
    BMC Health Serv Res; 2022 Jun; 22(1):741. PubMed ID: 35658941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Consumer reporting of adverse events following immunization (AEFI): identifying predictors of reporting an AEFI.
    Parrella A; Gold M; Braunack-Mayer A; Baghurst P; Marshall H
    Hum Vaccin Immunother; 2014; 10(3):747-54. PubMed ID: 24406315
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adverse event following vaccine surveillance in Kaduna State, Northwestern Nigeria (January 2018 -June 2019): analysis of health facility´s records.
    Ishaku SG; Umeh G; Adzu B; Onimisi A; Dauda M; Iyal HA; Iliyasu N; Sunday DJ; Daikwo J; Yates SM; Ibrahim II; Samaila LH; Abdullahi B; Parom SK; Maiwashi KY; Zakari F; Nuhu KS
    Pan Afr Med J; 2021; 40():268. PubMed ID: 35251462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.